| abstract |
The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding, while demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties. |